A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

• Status: Completed
• Trial end date: 2017-10-18
• Target enrollment: 0
• Participant gender: All

Summary

This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

-Normal vision at distance, either natural or post corneal laser refractive surgery, with presbyopia in each eye and complaints of poor near vision that impacts activities of daily living.

Exclusion Criteria:

• Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study

• Corneal abnormalities in either eye that interfere with visual acuity

• History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or any intraocular surgery

• Diagnosis of glaucoma or ocular hypertension.